Our web-accessible HLA peptide database HLA Compass comprises 1.4 million unique peptides and 10,000 cancer specific epitopes deriving from >17 million identifications in 4,160 high-quality HLA peptidomics samples, meticulously collected from healthy organs, cancer cell lines, and tumor tissues.

Predict which peptides will bind to specific HLA molecules — fast and reliably. Our AI-powered tools combine biological relevance and computational precision to support epitope discovery, vaccine design, and immunotherapy development.

A cutting-edge mass spectrometry service for ultra-sensitive profiling of HLA peptides directly from tumor or tissue samples. NeoZOOM helps you zoom in on the targets that matter most — with unmatched depth and accuracy.

Reduce risk before it reaches the clinic. Our platform integrates proprietary healthy tissue data and machine learning models to predict potential off-target peptide binding — helping you design safer TCR, TCRm, and antibody therapies.

Standardized kits for sample preparation and peptide enrichment, tailored for HLA immunopeptidomics workflows. Designed to ensure reproducibility, scalability, and compatibility with mass spectrometry and downstream analytics.

Latest HLA-Compass Updates Version history, new features, and improvements